Odile Belzunce - Innate Pharma VP Operations
| IPHA Stock | USD 1.54 0.04 2.67% |
Insider
Odile Belzunce is VP Operations of Innate Pharma
| Age | 44 |
| Address | 117, Avenue de Luminy, Marseille, France, 13009 |
| Phone | 33 4 30 30 30 30 |
| Web | https://www.innate-pharma.com |
Innate Pharma Management Efficiency
The company has return on total asset (ROA) of (0.1376) % which means that it has lost $0.1376 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7859) %, meaning that it created substantial loss on money invested by shareholders. Innate Pharma's management efficiency ratios could be used to measure how well Innate Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of November 30, 2024, Return On Tangible Assets is expected to decline to -0.04. In addition to that, Return On Capital Employed is expected to decline to -0.09. At present, Innate Pharma's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 55.5 M, whereas Total Current Assets are forecasted to decline to about 132.5 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Abhinav Shukla | Shattuck Labs | ||
| John CPA | MediciNova | N/A | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Wai Lee | Aptorum Group Ltd | 50 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Chung Huen | Aptorum Group Ltd | 44 | |
| David MBA | Champions Oncology | 55 | |
| Timothy Dyer | Addex Therapeutics | 56 | |
| James JD | Eliem Therapeutics | 58 | |
| Darren Lui | Aptorum Group Ltd | 42 | |
| Yuichi MD | MediciNova | 74 | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 65 | |
| Kenneth JD | Century Therapeutics | N/A | |
| MD MBA | Shattuck Labs | 65 | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| Mikhail Kalinichev | Addex Therapeutics | 57 | |
| Peter Rhode | HCW Biologics | 66 | |
| BS CMAR | Champions Oncology | N/A | |
| BS CPA | Inhibrx | 42 | |
| Andrew MBA | Shattuck Labs | 38 | |
| Quinn Deveraux | Inhibrx | N/A | |
Management Performance
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.14 |
Innate Pharma Leadership Team
Elected by the shareholders, the Innate Pharma's board of directors comprises two types of representatives: Innate Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Innate. The board's role is to monitor Innate Pharma's management team and ensure that shareholders' interests are well served. Innate Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Innate Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Odile Belzunce, VP Operations | ||
| Marc Bonneville, Founder | ||
| Jean Fourni, Founder | ||
| Henry MSc, Vice Communication | ||
| DVM MBA, VP Founder | ||
| Frederic MBA, Senior CFO | ||
| Sonia MD, Chief VP | ||
| Mondher MD, Chairman CEO | ||
| Herve Brailly, Interim CoFounder | ||
| Alessandro MD, Founder | ||
| Jonathan Dickinson, Chairman CEO | ||
| Yannis Morel, Exec Board | ||
| Franois Romagn, Founder | ||
| Arvind Sood, President VP |
Innate Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Innate Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (1.01) % | ||||
| Operating Margin | (2.13) % | ||||
| Current Valuation | 63.66 M | ||||
| Shares Outstanding | 80.95 M | ||||
| Shares Owned By Institutions | 0.50 % | ||||
| Number Of Shares Shorted | 63.72 K | ||||
| Price To Book | 4.10 X | ||||
| Price To Sales | 3.69 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.75) | Earnings Share (0.44) | Revenue Per Share 0.419 | Quarterly Revenue Growth (0.69) | Return On Assets (0.14) |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.